When you have cancer act as if there is no tomorrow, believe you will live forever; focus on your life not on the disease

Daniel Weber M health Sci.


Daniel Weber began his study of Oriental Medicine in 1969 in Boston. He studied with J. R. Worsley and J. D. van Buren in the UK from 1974 before receiving his B.Ac. Daniel went to Japan in 1976 and studied with Dr. Masahiro Oki and Dr. Okada. He has been in practice in Sydney Australia since 1977 and created the first English language data base for Chinese herbal medicine in 1992. This data base was awarded 'Innovations in Australian Design' and put on exhibit in the Powerhouse Museum.

Daniel has studied in China from 1988, visiting more than a dozen times with numerous awards and two honorary Ph.Ds as well as being an advisor to Hangzhou TCM Institute in Hangzhou. Daniel has a Master of Health Science (Aust) and is completing his research Doctorate. Daniel is not just an academic but a committed clinician, and continues a clinic as well as his ongoing studies. His research into complimentary cancer treatments and his seminars to practitioners in Australia, South Africa and the US have attracted positive comment from leaders in the field. He is committed to creating a dialogue between all types of health care professionals.

Antiproliferative activity herb extracts and breast cancer


Complementary and Alternative Medicine
Antiproliferative activity of 71 herb extracts was tested on breast cancer cells

2003 MAR 24 -- Antiproliferative activity of 71 herb extracts was tested on breast cancer cells.
According to a study from the United States, "Chinese medicinal herbs are traditionally used to prevent and treat a variety of diseases, including cancer. These herbal preparations are purported to have many biological effects including direct antiproliferative effects on cancer cells, antimutagenic activity, and stimulatory or suppressive effects on immune responses. The present study investigates the effects of aqueous extracts from 71 Chinese medicinal herbs on the growth of 5 breast cancer cell lines (SK-BR-3, MCF7, MDA-MB-231, BT-474 and MCNeuA).
"A total of 21% (15/71) of the extracts demonstrated greater than 50% growth inhibition on at least 4 of the 5 cell lines. Dose response curves were obtained for several of the most potent crude extracts and demonstrated IC50 values ranging from <10 microgr/ml to >1 mg/ml. Six of seven herbs tested induced high molecular weight DNA fragmentation, an early marker of apoptosis, while one of these also induced low molecular weight DNA fragmentation. Flow cytometric analysis of breast cancer cells exposed to one of these herbs (Rheum palmatum) suggested that it arrests cells in the G2/M phase of the cell cycle," stated M.J. Campbell and coauthors at University of California San Francisco's Mt. Zion Medical Center.
Campbell and coauthors concluded: "These results indicate that many of the herbs used in traditional Chinese medicine for the treatment of cancer have significant growth inhibitory effects on breast cancer cells in vitro."
Campbell and colleagues published the results of their study in Anticancer Research (Antiproliferative activity of Chinese medicinal herbs on breast cancer cells in vitro. Anticancer Res, 2002;22(6C):3843-3852).
The corresponding author for this report is M.J. Campbell, University of of California San Francisco, Mt Zion Med Center, Department Surgery, Rm C342, 1600 Divisadero, San Francisco, CA 94115, USA.
To subscribe to the journal Anticancer Research, contact the publisher: International Institute Anticancer Research, Editorial Office 1ST km Kapandritiou-Kalamou Rd. Kapandriti, PO Box 22, Athens 19014, Greece.
The information in this article comes under the major subject areas of Complementary and Alternative Medicine, Traditional Chinese Medicine, Herbal Extracts, Breast Cancer, Immunology, Oncology, Rheum palmatum, Growth Inhibition, Cell Science, Apoptosis, Antiproliferative Effect, Immune Stimulation, Immune Suppression, DNA Fragmentation, Herbal Therapy and Women's Health.
This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2003, Clinical Oncology Week via

 Clinical Oncology Week, March 24, 2003, page 7 

Allergy Medicine
Food allergies may be treatable with immunotherapy, anti-IgE antibodies, herbs

 2004 JAN 5 -- Treatments that may work against food allergy include immunotherapy, anti- immunoglobulin E (IgE) antibody therapy, and Chinese herbs.
"Up to 5% of young children and 2% of adults suffer from food allergy. Among them, many have IgE-mediated food allergy, a condition with potentially fatal allergic reactions. Several studies have addressed possible definite treatment options for food allergy," researchers in Switzerland report.
"Immunotherapy, by the oral route or by systemic injections, shows promising preliminary results, but current interpretation of these therapeutic options are mostly handicapped by studies with insufficient scientific support or by severe side effects.
"Currently, no studies can support pharmacotherapy. Finally, most promising results were recently published with anti-IgE antibodies in a human trial; also, various approaches in a mouse model of food allergy included Chinese herbal medicine and specific modulation of T cell responses," wrote P.A. Eigenmann and colleagues.
The researchers concluded: "Rapidly evolving findings might provide hope for a cure of food allergy in the near future."
Eigenmann and coauthors published their study in Allergy (Future therapeutic options in food allergy. Allergy, 2003;58(12):1217-1223).
For additional information, contact P.A. Eigenmann, Hop des Enfants, 6 Rue Willy Donze, CH-1211 Geneva 14, Switzerland.
Publisher contact information for the journal Allergy is: Blackwell Munksgaard, 35 Norre Sogade, PO Box 2148, DK-1016 Copenhagen, Denmark.
The information in this article comes under the major subject areas of Allergy Medicine, Biological Therapy, Hematology, Food Allergy, Anti-IgE Therapy, Proteomics, Complementary and Alternative Medicine, Drug Develpment, and Immunology.
This article was prepared by Health & Medicine Week editors from staff and other reports. Copyright 2004, Health & Medicine Week via

 Health & Medicine Week, January 5, 2004, page 30 

Complementary & Alternative Medicine
Chinese herbal medicine credited with successful lung cancer treatment

 2004 APR 12 -- A regimen of Chinese medicinal herbs has been credited with the successful treatment of a lung cancer patient.
According to published research from Australia, a "51-year-old woman diagnosed with squamous cell carcinoma (SCC) of the lung (T2N2M0) by cytological tests and a CT scan has survived for 8 years."
"During this period of time, she had been treated with Chinese herbal medicine alone for 4 years," reported H.L.M. Liang and coauthors at RMIT University in Bundoora. "The herbal prescription consisted of nine Chinese medicinal herbs. These herbs have been reported to possess antitumor and immune-enhancing effects."
"Therefore, it is suggested that the herbal treatment for this patient might have contributed to the complete regression of her lung carcinoma," the investigators concluded. "Further research on the actions of these herbs is warranted."
Liang and colleagues published their findings in Lung Cancer (Regression of squamous cell carcinoma of the lung by Chinese herbal medicine: a case with an 8-year follow-up. Lung Cancer-j Iaslc, 2004;43(3):355-360).
Additional information can be obtained by contacting C.C.L. Xue, RMIT University, RMIT Chinese Medicine Research Group, Bundoora West Campus, P.O. Box 71, Bundoora, Vic 3083, Australia.
The publisher of the journal Lung Cancer can be contacted at: Elsevier Science Ireland Ltd., Customer Relations Manager, Bay 15, Shannon Industrial Estate, Co, Clare, Ireland.
The information in this article comes under the major subject areas of Biotechnology, Complementary & Alternative Medicine, Immunology, Oncology, Pharmaceutical & Drug Development and Pulmonary Medicine.
This article was prepared by Health & Medicine Week editors from staff and other reports. Copyright 2004, Health & Medicine Week via

 Health & Medicine Week, April 12, 2004, page 148 

Complementary and Alternative Medicine
Chinese herbs exhibit antitumor effects in mouse lung tumor models

 2004 JUL 12 -- A mixture of Chinese herbs exhibited cancer chemopreventive activity in mouse lung tumor models.
According to a study from the United States, "Antitumor B (ATB), also known as Zeng Sheng Ping, is a Chinese herbal mixture composed of six plants. Previously, clinical studies have shown a significant chemopreventive efficacy of ATB against human esophageal and lung cancers. In the present study, A/J mice harboring a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf and treated with benzo[a] pyrene were used to investigate the chemopreventive effects of ATB on chemically induced lung tumorigenesis."
"Mice with various genotypes treated with ATB displayed a significant reduction in lung tumor multiplicity and tumor load," said Zhongqiu Zhang and colleagues at Washington University in St. Louis and the University of Alabama in Birmingham. "Treatment with ATB resulted in an approximately 40% decrease in tumor multiplicity and a 70% decrease in tumor load in both wild-type mice and in mice with a loss of the Ink4a/Arf tumor suppressor genes. Interestingly, ATB decreased tumor multiplicity and volume by 50 and 90%, respectively, in mice with a dominant-negative p53 and in mice with both a p53 mutation and deletion of Ink4a/Arf."
"Kras2 mutation analysis of the lung tumors revealed that tumors harbored mutations in the 12th codon of Kras2," stated the researchers. "There were no differences in either the incidence or types of mutations between tumors treated with or without ATB. Oligonucleotide array analysis revealed 284 genes that were differentially expressed in mouse lung tumors as compared to the normal lung, and it was found that 114 out of these 284 genes changed their expression toward the normal levels in tumors treated with ATB."
The investigators reported, "Most of the genes modulated by ATB belong to several cellular signaling pathways, including Notch (Notch homolog 2, manic fringe homolog), growth factor (FGF intracellular-binding protein, PDGFalpha), G protein-Ras-MAPK (MAPK3, MAP3K4, rab3A, Rap1, RSG5, PKCh), ubiquitin-proteasome (CDC34, Cullin1, 26S proteasome), and apoptosis (BAD promoter, caspase 3)."
The scientists concluded, "These results suggest that ATB is an effective chemopreventive against mouse lung tumorigenesis. Furthermore, ATB exhibited an enhanced inhibitory effect in animals harboring genetic alterations (Kras2, p53, and Ink4a/Arf), which are often seen in human lung adenocarcinomas."
Zhang and associates published the results of their research in Oncogene (Cancer chemopreventive activity of a mixture of Chinese herbs (Antitumor B) in mouse lung tumor models. Oncogene, 2004;23(21):3841-3850).
For additional information, contact Ming You, Department of Surgery, Washington University School of Medicine, Campus Box 8109, 660 South Euclid Avenue, St. Louis, MO 63110, USA. E-mail:
The publisher of the journal Oncogene can be contacted at: Nature Publishing Group, MacMillan Building, 4 Crinan Street, London N1 9XW, England.
The information in this article comes under the major subject areas of Complementary and Alternative Medicine, Lung Cancer, Carcinogenesis, Herbal Medicine, Pharmaceutical and Drug Development, and Oncology.
This article was prepared by Health & Medicine Week editors from staff and other reports. Copyright 2004, Health & Medicine Week via

 Health & Medicine Week, July 12, 2004, page 226 

Complementary & Alternative Medicine
Doctors say herbal blend can help cancer patients

 2005 JAN 17 -- Yale University, the Ivy League bastion of Western science, is turning to ancient Chinese formulas to develop new medicines for the 21st century.
Already physicians have demonstrated that an 1800-year-old Chinese recipe of four plants can apparently ease the side effects of chemotherapy while boosting the healing power of the anticancer drug.
These intriguing preliminary results must be expanded and reconfirmed, doctors said, but a crucial principle is clear - combinations of compounds could be the key to treating a variety of intractable diseases.
Specifically, researchers believe that modernized "polychemical" Chinese remedies hold hope for diseases like cancer, Alzheimer disease and other neurodegenerative diseases.
Yale is among a handful of American institutions exploring Chinese medicine and may be the closest to bringing an FDA-approved drug into clinical use.
Yale scientists have established PhytoCeutica, Inc., in New Haven, Connecticut, as a base of business operations and have already developed a unique method to ensure chemically consistent products.
The very antiquity of traditional Chinese medicine supports its effectiveness, said Dr. Edward Chu, chief of medical oncology at the Yale Cancer Center.
"Herbs have been used in the Orient for 2000 years with clear efficacy. Experience was passed down from generation to generation to generation. My great-grandfather was a Chinese herbalist," Chu said.
Chu is internationally recognized for his research on why abnormal cells proliferate and sprout into cancer. He is currently studying novel treatments for colon cancer.
Chu hopes to apply the same rigorous research methodology on herbal medicines.
"The essence of Chinese medicine is multiple ingredients and all are key. You may need two ingredients for efficacy and two to prevent toxicity," he said.
This is more than mere theory.
Chu and colleagues are working on a traditional medicine that they call PHY906.
PHY906 interested Chu because the medicine is traditionally used to ease gastrointestinal problems - the same kinds that plague people receiving chemotherapy for colon cancer.
Yale pharmacology professor Yung-Chi Cheng said the research team does not want to reveal the mixture's commercial name. This is because identically named products from several sources may have completely different ingredients, or may vary significantly from batch to batch.
In fact, Chinese medicine can only be integrated into the modern system if the compounds are rigidly consistent, Chu and Cheng said.
And that is a whole challenge unto itself.
"Modern medicine is only 50 years old, so there's a big gap. You either deny the history or you take advantage of its historical use," Cheng said.
Eventually, Chinese medicine will complement modern medicine, he said.
Western physicians are suspicious of Chinese medicine because it was developed empirically, rather than experimentally, Cheng said.
"Even if you have a medicine that is evidence-based, if you can't make it consistent, the material is not a medicine," Cheng said.
"If we can overcome those two issues, then Chinese medicine may be useful for unmet clinical needs," he said.
Yale conducted a clinical test of PHY906 on patients receiving chemotherapy. Out of 30 patients, 17 were evaluated, Cheng said.
The patients experienced less vomiting, nausea and diarrhea. And tumor progression was halted in all but two patients.
"This is very encouraging. It is a preliminary result," Cheng said.
Another study of PHY906 is under way on patients with liver cancer at Yale and at the City of Hope National Medical Center in Los Angeles.
The mixture seems to aid chemotherapy by increasing absorption in cells. PHY906 also apparently affects a protein involved in regulating cell proliferation, transformation and tumor development.
"This may be a totally novel way of treating diseases," Cheng said.
PHY906 contains 150 different chemicals, 90 of which have been identified. Eight of the compounds seem essential to the mixture's effectiveness.
The FDA has provisions to approve botanicals as prescription drugs, and PHY906 is going through the conventional testing process, he said.
"We want to shift the focus from single molecules to collections of molecules to add a new level to Western medicine," said Robert Tilton, vice president of science and technology at PhytoCeutica.
"In a way, we're rediscovering the past, but with rigorous methodology," he said.
This article was prepared by Health & Medicine Week editors from staff and other reports. Copyright 2005, Health & Medicine Week via

 Health & Medicine Week, January 17, 2005, page 281 

Complementary & Alternative Medicine
King of Herbs product lines launched; based on traditional Chinese medicine

 2005 OCT 17 -- China Health Holding, Inc., (CHHH), a developer and marketer and manufacturer of natural medicinal herbal supplement products based on traditional Chinese medicine, announced the launch of its first product line called King of Herbs, a proprietary enhanced natural herbal medicinal product line.
Inspired by thousands years of traditional Chinese medicine and Taoist medicine China Health Holding's product line is enhanced via a formula to strengthen the immune system and reinforce cardiovascular systems, according to the company.
The product line is also targeted at various common physiological conditions.
Considered a dietary supplement, China Health Holding's product lines are not required to receive U.S. Food & Drug Administration clearance prior to being sold. All China Health Holding's product lines are currently manufactured in accordance with good manufacturing standards and standards of appropriate regulatory bodies.
"We are delighted to launch this exciting powerful new product line," said Julianna Lu, president and CEO of China Health Holding. "Based upon the success that this product line has had in the People's Republic of China, we have high hopes for similar success in North America and internationally. We will shortly begin an ambitious global marketing campaign and branding campaign to sell this innovative product line and rapidly penetrate the global multibillion dollar natural health market."
This article was prepared by Health & Medicine Week editors from staff and other reports. Copyright 2005, Health & Medicine Week via

 Health & Medicine Week, October 17, 2005, page 449 

Complementary & Alternative Medicine
Herbal medicines may provide help for people with irritable bowel syndrome

 2006 FEB 6 -- Traditional herbal medicines may improve symptoms of abdominal pain, disturbed bowel movements, and/or bloating and distension caused by irritable bowel syndrome (IBS).
This was the conclusion of a systematic review of clinical studies published in the January 25, 2006, update of The Cochrane Library (Herbal medicines for treatment of irritable bowel syndrome. The Cochrane Database of Systematic Reviews, 2006;1. Art. No.: CD004116.pub2. DOI: 10.1002/14651858.CD004116.pub2).
Authors searched for studies that evaluated the effectiveness of traditional herbs including Chinese, Tibetan, and Indian herbal medicines and found 75 different randomized trials. The trials varied in quality, and investigated a wide range of different preparations. Most of the trials had been conducted in China and published in Chinese.
"Many of the trials were small, so it is premature to recommend herbal medicines for routine use in IBS, but there is evidence that some of the medicines did improve the global symptoms of IBS," says lead author Jianping Liu, who works both at the Evidence-based Chinese Medicine Centre for Clinical Research and Evaluation at Beijing University of Chinese Medicine, and at the National Research Centre in Complementary and Alternative Medicine (NAFKAM), University of Tromso, Norway.
Medicines that showed promise included Chinese herbal formulation and individualized herbal formulation; STW 5; SW 5_ii; as well as Tibetan herbal formula Padma Lax. The Chinese herbal medicine Tongxie Yaofang showed a statistically significant effect on global symptoms, as did the Indian Ayurvedic formula of two herbs.
Six small trials reported that combining conventional and herbal medicines produced greater benefits than using conventional therapies alone, but the authors believe that larger trials are needed to confirm this finding.
"There is a great need for further rigorously conducted trials that look to see whether it is possible to replicate these positive effects," says Liu.
One of the problems with comparing the results of different trials is the wide range of formulas used, and the imprecision with which different medicines are prepared.
"For these trials to be useful they must also improve the description of the herbal medicines being tested," adds Liu.
This article was prepared by Pain & Central Nervous System Week editors from staff and other reports. Copyright 2006, Pain & Central Nervous System Week via

 Pain & Central Nervous System Week, February 6, 2006, page 68 

Breast Cancer Therapy
Reports from New York Medical College, Department of Biochemistry and Molecular Biology describe recent advances in breast cancer therapy

 2006 NOV 13 -- New investigation results, "Differential control of growth, cell cycle progression, and gene expression in human estrogen receptor positive MCF-7 breast cancer cells by extracts derived from polysaccharopeptide I'm-Yunity and Danshen and their combination," are detailed in a study published in International Journal of Oncology. "The use of herbs has been the mainstay of treatment for a variety of human illnesses and is an essential part of culturally-based healing traditions in many societies and countries. Also, herbs, including Chinese herbs, are being incorporated as remedies for disease management and treatment in Western countries," scientists in the United States report.
"In Traditional Chinese Medicine (TCM), herbal prescriptions are most frequently given to patients as complex formulations containing multiple herbs. Notably and unwittingly, this approach amounts to the administration of several chemical entities at once; the underlying theory is that interactions among the chemicals present in different herbs in a formula exert synergistic pharmacodynamic actions and neutralize the adverse effects and toxicities of specific individual chemicals. The effectiveness and mechanisms of this approach have not been well investigated or understood. A primary interest of this laboratory is to obtain experimental evidence that supports the fundamental mechanistic theme for the combinatorial herbal strategy described above and its potential application in preventing and treating breast cancer (BCa). In this study, we investigated the effects of 70% ethanolic extracts prepared from medicinal mushroom extract denoted I'm-Yunity and Danshen (Salvia miltiorrhizae Binge), alone and in combination, using MCF-7 cells as an in vitro model of estrogen receptor positive (ER+), low invasive BCa. Combination of I'm-Yunity and Danshen (referred to as I'm-Yunity-Plus) suppressed clonogenicity to a comparable degree as Danshen alone; both being significantly more active than I'm-Yunity. However, extract of Danshen was more active in inhibiting MCF-7 cell growth than I'm-Yunity-Plus. In comparison, I'm-Yunity elicited less growth inhibition. Flow cytometric analysis showed that I'm-Yunity-Plus induced partial block of G1/S transition in MCF-7 cells, whereas Danshen slowed down cell progression from G1/S into G2/M phases of the cell cycle. Treatment by I'm-Yunity did not affect cell cycle progression in MCF-7 cells; however, it promoted active induction of apoptosis. In addition, treatment with Danshen alone resulted in a pronounced reduction in the expression of Rb, cyclin D1, and p53, and also led to a diminution of p65 and p50 forms of NF-kappaB. The pronounced suppressive effects of Danshen on expression of the aforementioned genes were largely attenuated in cells treated with I'm-Yunity-Plus suggesting that ingredients in Danshen must have interacted with those in I'm-Yunity as to culminate in neutralization of the gene suppressive effects of Danshen. Additional support for such interactions was obtained by targeted cDNA array analysis using human tumor metastasis and BCa/ER signaling gene arrays," wrote T.C. Hsieh and colleagues, New York Medical College, Department of Biochemistry and Molecular Biology.
The researchers concluded: "Taken together, our results are consistent with the interpretation that interaction exists between Danshen and I'm-Yunity and that I'm-Yunity-Plus may have efficacy in the treatment of BCa, particularly for patients with ER+ status."
Hsieh and colleagues published their study in International Journal of Oncology (Differential control of growth, cell cycle progression, and gene expression in human estrogen receptor positive MCF-7 breast cancer cells by extracts derived from polysaccharopeptide I'm-Yunity and Danshen and their combination. International Journal of Oncology, 2006;29(5):1215-22).
For more information, contact T.C. Hsieh, New York Medical College, Dept. of Biochemistry and Molecular Biology, Valhalla, NY 10595 U.S.
Publisher contact information for the International Journal of Oncology is: Professor D a Spandidos, 1, S Merkouri St., Editorial Office, Athens 116 35, Greece.
Keywords: United States, Valhalla, Breast Cancer Therapy, Biochemistry, Breast Cancer, Breast Carcinoma, Oncology, Tumors, Women's Health.
This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2006, Clinical Oncology Week via

 Clinical Oncology Week, November 13, 2006, page 250 

Investigators at Zhejiang University, College of Life Sciences target pharmacology

 2007 JAN 23 -- New research, "Database of traditional Chinese medicine and its application to studies of mechanism and to prescription validation," is the subject of a report. "Traditional Chinese Medicine (TCM) is widely practised and is viewed as an attractive alternative to conventional medicine. Quantitative information about TCM prescriptions, constituent herbs and herbal ingredients is necessary for studying and exploring TCM," investigators in Hangzhou, People's Republic of China report.
"EXPERIMENTAL APPROACH: We manually collected information on TCM in books and other printed sources in Medline. The Traditional Chinese Medicine Information Database TCM-ID, at, was introduced for providing comprehensive information about all aspects of TCM including prescriptions, constituent herbs, herbal ingredients, molecular structure and functional properties of active ingredients, therapeutic and side effects, clinical indication and application and related matters. TCM-ID currently contains information for 1,588 prescriptions, 1,313 herbs, 5,669 herbal ingredients, and the 3D structure of 3,725 herbal ingredients. The value of the data in TCM-ID was illustrated by using some of the data for an in-silico study of molecular mechanism of the therapeutic effects of herbal ingredients and for developing a computer program to validate TCM multi-herb preparations. The development of systems biology has led to a new design principle for therapeutic intervention strategy, the concept of 'magic shrapnel' (rather than the 'magic bullet'), involving many drugs against multiple targets, administered in a single treatment. TCM offers an extensive source of examples of this concept in which several active ingredients in one prescription are aimed at numerous targets and work together to provide therapeutic benefit," wrote X. Chen and colleagues, Zhejiang University, College of Life Sciences.
The researchers concluded: "The database and its mining applications described here represent early efforts toward exploring TCM for new theories in drug discovery."
Chen and colleagues published their study in British Journal of Pharmacology (Database of traditional Chinese medicine and its application to studies of mechanism and to prescription validation. British Journal of Pharmacology, 2006;149(8):1092-103).
For additional information, contact X. Chen, College of Life Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
The publisher of the British Journal of Pharmacology can be contacted at: Nature Publishing Group, Macmillan Building, 4 Crinan St., London N1 9XW, England.
Keywords: People's Republic of China, Hangzhou, Pharmacology, Therapy.
This article was prepared by Drug Law Week editors from staff and other reports. Copyright 2007, Drug Law Week via

 Drug Law Week, January 23, 2007, page 822 

Marketing and Licensing Agreements
Research from Chinese University of Hong Kong provide new insights into marketing and licensing agreements

 2007 MAR 5 -- Researchers detail in "A practical way of research in Chinese medicine," new data in marketing and licensing agreements. According to recent research published in the journal Annals of the Academy of Medicine, Singapore, "While modern medicine has a very well established system of clinical research which insists on evidence-based methodology, traditional medicine has not developed its own system of research, despite of its length of existence and unreceding popularity. Since there are still many problem areas in modern medicine, and traditional medicine possesses good records of efficacy in those areas, it is natural that experts in both areas should collaborate in a proper exploration to put traditional medicine into popular utilisation."
"One way of achieving this is to follow the requirements of modern clinical trials as much as possible. Obvious obstacles include the uncertain origin of supply of herbs and the inconsistency of their quality, manufacturing of convenient products (which has improved) and methodology for clinical trials," wrote P.C Leung and colleagues, Chinese University of Hong Kong.
The researchers concluded: "One practical way in pursuing this joint venture is to apply the efficacy-driven approach, which suggests the following: i) Using a simple herbal formula to try solving one difficult clinical problem and start an evidence-based clinical trial using methodology acceptable to standard clinical trials i.e., one which is randomised and placebo-controlled; ii) Organising parallel laboratory experiments to understand the mode of action; iii) Making sure that the quality of herbs or their extracts are of the best standard; and iv) Optimising the formula, once it is proven efficacious in a clinical trial, to give an upgraded product."
Leung and colleagues published their study in Annals of the Academy of Medicine, Singapore (A practical way of research in Chinese medicine. Annals of the Academy of Medicine, Singapore, 2006;35(11):770-2).
For additional information, contact P.C. Leung, The Chinese University of Hong Kong, Institute of Chinese Medicine, Hong Kong.
The publisher's contact information for the journal Annals of the Academy of Medicine, Singapore is: Acad Medicine Singapore, 142 Neil Rd., Republic Singapore 088871, Singapore.
Keywords: Hong Kong, Clinical Trials Research, Marketing and Licensing Agreements.
This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via

 Biotech Business Week, March 5, 2007, page 1028 

Research results from National University of Singapore, Department of Pharmacy update knowledge of ethnopharmacology

 2007 FEB 12 -- A new study, "Usefulness of traditionally defined herbal properties for distinguishing prescriptions of traditional Chinese medicine from non-prescription recipes," is now available. According to a study from Singapore, Singapore, "Traditional Chinese medicine (TCM) has been widely practiced and is considered as an attractive to conventional medicine. Multi-herb recipes have been routinely used in TCM."
"These have been formulated by using TCM-defined herbal properties (TCM-HPs), the scientific basis of which is unclear. The usefulness of TCM-HPs was evaluated by analyzing the distribution pattern of TCM-HPs of the constituent herbs in 1161 classical TCM prescriptions, which shows patterns of multi-herb correlation. Two artificial intelligence (AI) methods were used to examine whether TCM-HPs are capable of distinguishing TCM prescriptions from non-TCM recipes. Two AI systems were trained and tested by using 1161 TCM prescriptions, 11,202 non-TCM recipes, and two separate evaluation methods. These systems correctly classified 83.1-97.3% of the TCM prescriptions, 90.8-92.3% of the non-TCM recipes," wrote C.Y. Ung and colleagues, National University of Singapore, Department of Pharmacy.
The researchers concluded: "These results suggest that TCM-HPs are capable of separating TCM prescriptions from non-TCM recipes, which are useful for formulating TCM prescriptions and consistent with the expected correlation between TCM-HPs and the physicochemical properties of herbal ingredients responsible for producing the collective pharmacological and other effects of specific TCM prescriptions."
Ung and colleagues published their study in the Journal of Ethnopharmacology (Usefulness of traditionally defined herbal properties for distinguishing prescriptions of traditional Chinese medicine from non-prescription recipes. Journal of Ethnopharmacology, 2007;109(1):21-8).
For more information, contact C.Y. Ung, National University of Singapore, National University of Singapore, Dept. of Pharmacy, Blk SOC1, Level 7, 3 Science Drive 2, Singapore 117543, Singapore.
Publisher contact information for the Journal of Ethnopharmacology is: Elsevier Science Ireland Ltd., Customer Relations Manager, Bay 15, Shannon Industrial Estate, Co. Clare, Ireland.
Keywords: Singapore, Singapore, Ethnopharmacology, Pharmaceuticals.
This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via

 Biotech Business Week, February 12, 2007, page 694